Sophiris Bio, Inc. (SPHS)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0271+0.0000 (+0.18%)
At close: 3:24PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 0.0271 |
| Open | 0.0225 |
| Bid | 0.0000 x 2200 |
| Ask | 0.0000 x 800 |
| Day's Range | 0.0225 - 0.0342 |
| 52 Week Range | 0.0100 - 0.3100 |
| Volume | 107,800 |
| Avg. Volume | 380,688 |
| Market Cap | 935,917 |
| Beta (5Y Monthly) | 1.50 |
| PE Ratio (TTM) | 27.15 |
| EPS (TTM) | 0.0010 |
| Earnings Date | Nov 09, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- PR Newswire
Sophiris Bio To Shut Down Operations
Sophiris Bio Inc. (OTCQB: SPHS) (the "Company" or "Sophiris"), today announced that its board of directors has formally approved an immediate shutdown of the operations of the Company. The Company has been unable to find a partner or raise capital to support the continued development of topsalysin in either benign prostatic hyperplasia or localized prostate cancer.
© 2021 Verizon Media. All rights reserved.
